Literature DB >> 25756144

Human papillomavirus vaccination for boys.

Stephany Quinn, Ran D Goldman.   

Abstract

QUESTION: In Canada, generally provincial human papillomavirus (HPV) vaccination programs exist for only the female population. What should I recommend when parents and teenage boys ask about male HPV vaccination? ANSWER: The quadrivalent HPV vaccine is effective and will reduce the incidence of disease in boys and girls. The quadrivalent HPV vaccination is approved and recommended for both boys and girls in Canada. Public funding for male vaccination is available in Prince Edward Island and Alberta. The remaining provinces and territories will need to consider cost-effectiveness analyses before expanding their female-only vaccination programs to include the male population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25756144      PMCID: PMC4301763     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  19 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Human papillomavirus vaccine for children and adolescents.

Authors: 
Journal:  Paediatr Child Health       Date:  2007-09       Impact factor: 2.253

3.  Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.

Authors:  Igor A Korostil; Hammad Ali; Rebecca J Guy; Basil Donovan; Matthew G Law; David G Regan
Journal:  Sex Transm Dis       Date:  2013-11       Impact factor: 2.830

4.  Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.

Authors:  Stephen E Goldstone; Heiko Jessen; Joel M Palefsky; Anna R Giuliano; Edson D Moreira; Eftyhia Vardas; Carlos Aranda; Richard J Hillman; Daron G Ferris; Francois Coutlee; J Brooke Marshall; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth Garner
Journal:  Vaccine       Date:  2013-07-02       Impact factor: 3.641

5.  Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

Authors:  Basil Donovan; Neil Franklin; Rebecca Guy; Andrew E Grulich; David G Regan; Hammad Ali; Handan Wand; Christopher K Fairley
Journal:  Lancet Infect Dis       Date:  2010-11-08       Impact factor: 25.071

6.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

Review 7.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

8.  Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men.

Authors:  Edson Duarte Moreira; Anna R Giuliano; Joel Palefsky; Carlos Aranda Flores; Stephen Goldstone; Daron Ferris; Richard J Hillman; Harald Moi; Mark H Stoler; Brooke Marshall; Scott Vuocolo; Dalya Guris; Richard M Haupt
Journal:  J Infect Dis       Date:  2014-02-04       Impact factor: 5.226

9.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08

10.  Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Authors:  Emily A Burger; Stephen Sy; Mari Nygård; Ivar S Kristiansen; Jane J Kim
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

View more
  10 in total

Review 1.  Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.

Authors:  Mohamed-Béchir Ben Hadj Yahia; Anaïs Jouin-Bortolotti; Benoît Dervaux
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

2.  Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence.

Authors:  Didik Setiawan; Abrham Wondimu; KohJun Ong; Albert Jan van Hoek; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

Review 3.  Update on the new 9-valent vaccine for human papillomavirus prevention.

Authors:  David Yi Yang; Keyna Bracken
Journal:  Can Fam Physician       Date:  2016-05-12       Impact factor: 3.275

Review 4.  HPV Vaccine Uptake Among Canadian Youth and The Role of the Nurse Practitioner.

Authors:  Katlyn Scott; Mary Lou Batty
Journal:  J Community Health       Date:  2016-02

5.  Knowledge, attitude, and practice on and willingness to pay for human papillomavirus vaccine: a cross-sectional study in Hanoi, Vietnam.

Authors:  Bach Xuan Tran; Phung Tat Quoc Than; Tien Thuy Ngoc Doan; Huong Lan Thi Nguyen; Hue Thi Mai; Trang Huyen Thi Nguyen; Huong Thi Le; Carl A Latkin; Melvyn Wb Zhang; Roger Cm Ho
Journal:  Patient Prefer Adherence       Date:  2018-05-30       Impact factor: 2.711

6.  Knowledge, attitude, and practices regarding human papillomavirus and its' vaccination among the young medical professionals and students of Bangladesh.

Authors:  Sreshtha Chowdhury; Rifat Ara; Simanta Roy; Syed Md Sayeem Tanvir; Fahima Nasrin Eva; Tasnova Mehrin Neela; Amena Akter Moonmoon; Shamma Sifat; Mushfera Zamila; Mohammad Delwer Hossain Hawlader
Journal:  Clin Exp Vaccine Res       Date:  2022-01-31

7.  How can we use bibliometric analysis to guide research forward?-an editorial for "Research trends and hotspots on human papillomavirus: a bibliometric analysis of 100 most-cited articles".

Authors:  Mette H Nonboe; Elsebeth Lynge
Journal:  Ann Transl Med       Date:  2022-08

8.  Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies.

Authors:  Serra Lem Asangbeh-Kerman; Maša Davidović; Katayoun Taghavi; James Kachingwe; Kereng Molly Rammipi; Laura Muzingwani; Magaret Pascoe; Marielle Jousse; Masangu Mulongo; Mulindi Mwanahamuntu; Neo Tapela; Oluwasanmi Akintade; Partha Basu; Xolisile Dlamini; Julia Bohlius
Journal:  BMC Public Health       Date:  2022-08-10       Impact factor: 4.135

9.  Designing and psychometric assessment of the scale of factors influencing HPV vaccine uptake behaviors in young adults.

Authors:  Soudabeh Yarmohammadi; Mohtasham Ghaffari; Yadollah Mehrabi; Samira Mousavi; Ali Ramezankhani
Journal:  Infect Agent Cancer       Date:  2022-09-10       Impact factor: 3.698

10.  Monitoring the impact of HPV vaccine in males-Considerations and challenges.

Authors:  Julia M L Brotherton; Anna R Giuliano; Lauri E Markowitz; Eileen F Dunne; Gina S Ogilvie
Journal:  Papillomavirus Res       Date:  2016-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.